Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BEAM Stock Forecast 2025-2026
$19.52
Current Price
$2.03B
Market Cap
Buy 14
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to BEAM Price Targets
+309.8%
To High Target of $80.00
+115.2%
To Median Target of $42.00
+2.5%
To Low Target of $20.00
BEAM Price Momentum
+7.0%
1 Week Change
-12.1%
1 Month Change
-8.7%
1 Year Change
-21.3%
Year-to-Date Change
-44.6%
From 52W High of $35.25
+44.3%
From 52W Low of $13.53
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Beam Therapeutics (BEAM) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on BEAM and similar high-potential opportunities.
Latest BEAM Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, BEAM has a bullish consensus with a median price target of $42.00 (ranging from $20.00 to $80.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $19.52, the median forecast implies a 115.2% upside. This outlook is supported by 14 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick Trucchio at HC Wainwright & Co., projecting a 309.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BEAM Analyst Ratings
14
Buy
2
Hold
0
Sell
BEAM Price Target Range
Low
$20.00
Average
$42.00
High
$80.00
Current: $19.52
Latest BEAM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BEAM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 7, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $80.00 |
| Mar 28, 2025 | B of A Securities | Alec Stranahan | Buy | Upgrade | $42.00 |
| Mar 12, 2025 | Cantor Fitzgerald | Rick Bienkowski | Overweight | Reiterates | $0.00 |
| Mar 10, 2025 | Jones Trading | Soumit Roy | Buy | Upgrade | $34.00 |
| Mar 10, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $80.00 |
| Mar 10, 2025 | Scotiabank | Greg Harrison | Sector Outperform | Upgrade | $40.00 |
| Mar 3, 2025 | Scotiabank | Greg Harrison | Sector Perform | Maintains | $25.00 |
| Feb 28, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $80.00 |
| Feb 27, 2025 | Guggenheim | Debjit Chattopadhyay | Buy | Reiterates | $78.00 |
| Feb 26, 2025 | RBC Capital | Luca Issi | Sector Perform | Maintains | $26.00 |
| Feb 3, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $80.00 |
| Jan 29, 2025 | Cantor Fitzgerald | Rick Bienkowski | Overweight | Upgrade | $0.00 |
| Dec 9, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $80.00 |
| Nov 7, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $80.00 |
| Nov 6, 2024 | RBC Capital | Luca Issi | Sector Perform | Maintains | $24.00 |
| Nov 6, 2024 | Leerink Partners | Rick Bienkowski | Outperform | Upgrade | $39.00 |
| Oct 16, 2024 | Scotiabank | Greg Harrison | Sector Perform | Initiates | $24.00 |
| Sep 19, 2024 | RBC Capital | Luca Issi | Sector Perform | Reiterates | $27.00 |
| Sep 17, 2024 | Jones Trading | Soumit Roy | Hold | Initiates | $0.00 |
| Sep 11, 2024 | Stifel | Benjamin Burnett | Buy | Maintains | $69.00 |
Beam Therapeutics Inc. (BEAM) Competitors
The following stocks are similar to Beam Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BEAM
Beam Therapeutics
mkt cap
2.03B
Beam Therapeutics Inc. (BEAM) Financial Data
Beam Therapeutics Inc. has a market capitalization of $2.03B with a P/E ratio of -4.3x. The company generates $63.52M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -90.5% quarter-over-quarter, while maintaining an operating margin of -332.7% and return on equity of -43.9%.
Valuation Metrics
Market Cap
$2.03B
Enterprise Value
$893.98M
P/E Ratio
-4.3x
PEG Ratio
-4.1x
Price/Sales
31.9x
Growth & Margins
Revenue Growth (YoY)
-90.5%
Gross Margin
N/A
Operating Margin
-332.7%
Net Margin
0.0%
EPS Growth
-90.5%
Financial Health
Cash/Price Ratio
+53.7%
Current Ratio
4.8x
Debt/Equity
22.0x
ROE
-43.9%
ROA
-20.3%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Beam Therapeutics Inc. (BEAM) Business Model
About Beam Therapeutics Inc.
What They Do
Develops precision genetic medicines using base editing.
Business Model
Beam Therapeutics generates revenue by developing innovative genetic therapies that target and correct genetic disorders at a molecular level. By focusing on base editing technology, the company aims to license its therapies to pharmaceutical partners and potentially commercialize its own products, thus creating multiple revenue streams in the healthcare sector.
Additional Information
Founded in 2017 and based in Cambridge, Massachusetts, Beam Therapeutics is positioned as a leader in the genetic medicine field. The company's unique approach minimizes the risks associated with traditional gene-editing methods and addresses a range of conditions, including sickle cell disease and beta-thalassemia, which could significantly improve patient outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
483
CEO
Mr. John M. Evans M.B.A.
Country
United States
IPO Year
2020
Website
beamtx.comBeam Therapeutics Inc. (BEAM) Latest News & Analysis
Latest News
Quick Summary
Data shows that 28 days after BEAM-302 treatment at a 60 mg dose, the corrected M-AAT reached a mean of 91% of total AAT in circulation in a cohort of 3 participants.
Why It Matters
The data indicates a successful treatment outcome for BEAM-302, potentially enhancing market confidence and driving stock value for related biotech firms.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Biotech investors face uncertainty after the sudden resignation of Dr. Peter Marks, a significant official at the US FDA.
Why It Matters
Dr. Marks' resignation creates uncertainty in regulatory processes for biotech firms, potentially impacting drug approvals and stock performance in the sector.
Source: Invezz
Market Sentiment:
Negative
Power Ranking Our Top Stock Picks of 2025
27 days ago
Quick Summary
On March 30, subscribers to Chart of the Week received a commentary, indicating ongoing analysis and insights relevant for investors.
Why It Matters
Subscription updates indicate ongoing engagement and value in market analysis, potentially influencing investor sentiment and decision-making.
Source: Schaeffers Research
Market Sentiment:
Positive
Quick Summary
U.S. IND approval granted for BEAM-302 across six countries, marking Beam's second open IND for its in vivo base editing program in the U.S.
Why It Matters
Regulatory clearance for BEAM-302 across six countries and a second U.S. IND boosts confidence in Beam's pipeline, potentially leading to market expansion and revenue growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The FDA has approved Beam Therapeutics' investigational new drug application for BEAM-302, targeting alpha-1 antitrypsin deficiency in the U.S.
Why It Matters
FDA clearance for BEAM-302 boosts Beam Therapeutics' market potential, signaling progress in drug development and potentially increasing stock value and investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy
1 month ago
Quick Summary
BEAM reported positive Phase 1/2 results for BEAM-302, showing durable gene correction for AATD. However, a $500 million equity offering raises concerns about potential dilution.
Why It Matters
BEAM's promising gene therapy results for AATD boost its long-term value, but the $500 million equity offering raises immediate dilution concerns, affecting short-term investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About BEAM Stock
What is Beam Therapeutics Inc.'s (BEAM) stock forecast for 2025?
Based on our analysis of 19 Wall Street analysts, Beam Therapeutics Inc. (BEAM) has a median price target of $42.00. The highest price target is $80.00 and the lowest is $20.00.
Is BEAM stock a good investment in 2025?
According to current analyst ratings, BEAM has 14 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $19.52. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BEAM stock?
Wall Street analysts predict BEAM stock could reach $42.00 in the next 12 months. This represents a 115.2% increase from the current price of $19.52. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Beam Therapeutics Inc.'s business model?
Beam Therapeutics generates revenue by developing innovative genetic therapies that target and correct genetic disorders at a molecular level. By focusing on base editing technology, the company aims to license its therapies to pharmaceutical partners and potentially commercialize its own products, thus creating multiple revenue streams in the healthcare sector.
What is the highest forecasted price for BEAM Beam Therapeutics Inc.?
The highest price target for BEAM is $80.00 from Patrick Trucchio at HC Wainwright & Co., which represents a 309.8% increase from the current price of $19.52.
What is the lowest forecasted price for BEAM Beam Therapeutics Inc.?
The lowest price target for BEAM is $20.00 from at , which represents a 2.5% increase from the current price of $19.52.
What is the overall BEAM consensus from analysts for Beam Therapeutics Inc.?
The overall analyst consensus for BEAM is bullish. Out of 19 Wall Street analysts, 14 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $42.00.
How accurate are BEAM stock price projections?
Stock price projections, including those for Beam Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 11:08 AM UTC